Drug Price Trends for ALOGLIPTIN-METFORMIN

Average Pharmacy Cost for ALOGLIPTIN-METFORMIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ALOGLIPTIN-METFORMIN 12.5-1000	45802-0211-72	2.42229	EACH	2025-04-23
ALOGLIPTIN-METFORMIN 12.5-500	45802-0169-72	2.44611	EACH	2025-04-23
ALOGLIPTIN-METFORMIN 12.5-1000	45802-0211-72	2.39179	EACH	2025-03-19
ALOGLIPTIN-METFORMIN 12.5-500	45802-0169-72	2.46017	EACH	2025-03-19
ALOGLIPTIN-METFORMIN 12.5-1000	45802-0211-72	2.39669	EACH	2025-02-19
ALOGLIPTIN-METFORMIN 12.5-500	45802-0169-72	2.50258	EACH	2025-02-19
ALOGLIPTIN-METFORMIN 12.5-1000	45802-0211-72	2.42171	EACH	2025-01-22

Market Analysis and Price Projections for Alogliptin-Metformin

Introduction to Alogliptin-Metformin

Alogliptin-metformin is a combination drug used to treat type 2 diabetes. It combines alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with metformin, a biguanide. This combination is often prescribed to enhance glycemic control in patients who do not achieve adequate control with either drug alone.

Market Size and Growth

The oral anti-diabetic drugs market, which includes alogliptin-metformin, is expected to grow significantly over the coming years. Here are some key market insights:

• Global Market: The oral anti-diabetic drugs market is projected to reach USD 57.44 billion by 2029, growing at a CAGR of 4.17% from 2024 to 2029[4].
• Segment Share: The biguanide segment, which includes metformin, holds the highest market share, approximately 45% of the oral anti-diabetic drugs market. This is due to metformin's favorable risk/benefit profile, clinical efficacy, safety, and cost-effectiveness[4].

Price Dynamics

The pricing of alogliptin-metformin is influenced by several factors, including the cost of its individual components and market competition.

• Current Pricing: The cost for alogliptin-metformin (12.5 mg-500 mg or 12.5 mg-1000 mg) oral tablets can range from $208.40 for a supply of 60 tablets, depending on the pharmacy and any discounts applied[2].
• Comparison with Other DPP-4 Inhibitors: Alogliptin, when compared to other DPP-4 inhibitors like linagliptin, saxagliptin, and sitagliptin, is generally less expensive. For instance, alogliptin's daily cost is $2.62, which is lower than sitagliptin ($2.95) and saxagliptin ($2.84) but higher than linagliptin ($2.25 to $2.55)[3].

Market Projections

Here are some projections and trends that could impact the pricing and market size of alogliptin-metformin:

• Regional Growth: The Asia-Pacific region is expected to witness the highest CAGR in the oral anti-diabetic drugs market due to the growing diabetic population. Countries like China and Japan are key markets, with Japan seeing an increase in generic drug manufacturers[4].
• Competition and Generic Drugs: The market is becoming increasingly competitive with the entry of generic drugs. For example, Glenmark Pharmaceuticals introduced affordable sitagliptin-based drugs in India, which could influence pricing strategies for other DPP-4 inhibitors like alogliptin[4].

Cost Impact and Pharmacoeconomic Analysis

Pharmacoeconomic analyses provide insights into the cost-effectiveness of alogliptin-metformin compared to other treatments.

• Cost Savings: Alogliptin is expected to introduce cost savings compared to other DPP-4 inhibitors. For instance, it could result in annual savings of up to $122.28 when compared to sitagliptin and saxagliptin as second-line treatments[3].
• Market Average Cost: The weighted market average cost analysis shows that alogliptin is less expensive than the average cost of current DPP-4 inhibitors, indicating potential cost savings for healthcare systems[3].

Market Segmentation

The oral anti-diabetic drugs market, including alogliptin-metformin, is segmented based on drug types and geography.

• Drug Types: The market includes biguanides (metformin), DPP-4 inhibitors (alogliptin, sitagliptin, linagliptin), SGLT-2 inhibitors, and other classes. Alogliptin-metformin falls under the DPP-4 inhibitor and biguanide segments[4].
• Geography: The market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America. The Asia-Pacific region is expected to drive significant growth due to its large and growing diabetic population[4].

Key Players and Competitive Landscape

The competitive landscape for alogliptin-metformin includes several major pharmaceutical companies.

• Key Players: Companies like Novartis, Apotex, Viatris, Mallinckrodt, Teva Pharmaceuticals, and others are key players in the metformin market, while companies like Takeda (manufacturer of Nesina, the brand name for alogliptin) are significant in the DPP-4 inhibitor market[1][3].

Future Trends and Innovations

The oral anti-diabetic drugs market is evolving with new innovations and trends.

• New Molecules and Delivery Methods: Innovations such as oral insulin capsules and oral GLP-1 analogs are being developed, which could change the market dynamics and pricing strategies in the future. For example, Oramed's ORMD-0801, an oral insulin capsule, is in Phase 3 trials and could be a game-changer in insulin and oral anti-diabetes treatment[4].

Price Projections

Given the current market trends and competitive landscape, here are some price projection insights:

• Short-Term Pricing: The current pricing of alogliptin-metformin is expected to remain competitive, with prices potentially stabilizing around the current range of $208.40 for 60 tablets, depending on pharmacy discounts and insurance plans[2].
• Long-Term Pricing: As the market grows and more generic versions enter, there could be downward pressure on prices. However, the introduction of new and innovative treatments might balance this effect, maintaining a stable to slightly increasing price trend over the long term.

Key Takeaways

• Market Growth: The oral anti-diabetic drugs market is expected to grow significantly, driven by the Asia-Pacific region.
• Pricing Dynamics: Alogliptin-metformin is competitively priced compared to other DPP-4 inhibitors and is expected to offer cost savings.
• Competition: The market is highly competitive, with key players influencing pricing strategies.
• Innovations: New molecules and delivery methods are being developed, which could impact future market dynamics.

FAQs

Q: What is the current market size of the oral anti-diabetic drugs market? A: The oral anti-diabetic drugs market is expected to reach USD 46.82 billion in 2024 and grow to USD 57.44 billion by 2029[4].

Q: How does the pricing of alogliptin-metformin compare to other DPP-4 inhibitors? A: Alogliptin is generally less expensive than sitagliptin and saxagliptin but more expensive than linagliptin[3].

Q: What are the key regions driving growth in the oral anti-diabetic drugs market? A: The Asia-Pacific region is expected to witness the highest CAGR due to the growing diabetic population in countries like China and Japan[4].

Q: Are there any new innovations in the oral anti-diabetic drugs market that could impact pricing? A: Yes, innovations such as oral insulin capsules and oral GLP-1 analogs are being developed, which could change market dynamics and pricing strategies in the future[4].

Q: Which companies are key players in the alogliptin-metformin market? A: Companies like Novartis, Apotex, Viatris, and Takeda (manufacturer of Nesina) are significant players in this market[1][3].

Sources

1. Metformin Hydrochloride Tablet - Market Size - Valuates Reports
2. Alogliptin/metformin Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
3. CDR Pharmacoeconomic Review Report for Nesina - Canada.ca
4. Oral Anti Diabetic Drugs Market - Size, Share & Industry Analysis - Mordor Intelligence
5. Market Intelligence Report: Antidiabetic Drugs, 2012-2021 - Canada.ca